

Bernt Johan von Scholten

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3108317/publications.pdf>

Version: 2024-02-01

70
papers

2,007
citations

201385

27
h-index

276539

41
g-index

75
all docs

75
docs citations

75
times ranked

3265
citing authors

#	ARTICLE	IF	CITATIONS
1	Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 301-312.	5.5	166
2	Global Changes in Food Supply and the Obesity Epidemic. <i>Current Obesity Reports</i> , 2016, 5, 449-455.	3.5	143
3	Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease. <i>Circulation</i> , 2018, 138, 2908-2918.	1.6	88
4	Trimethylamine N-oxide (TMAO) as a New Potential Therapeutic Target for Insulin Resistance and Cancer. <i>Current Pharmaceutical Design</i> , 2017, 23, 3699-3712.	0.9	87
5	Anti-interleukin-21 antibody and liraglutide for the preservation of β -cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 212-224.	5.5	85
6	The effect of liraglutide on renal function: A randomized clinical trial. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 239-247.	2.2	77
7	Current and future therapies for type 1 diabetes. <i>Diabetologia</i> , 2021, 64, 1037-1048.	2.9	65
8	Cardiac ^{82}Rb PET/CT for fast and non-invasive assessment of microvascular function and structure in asymptomatic patients with type 2 diabetes. <i>Diabetologia</i> , 2016, 59, 371-378.	2.9	63
9	Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment. <i>Diabetic Medicine</i> , 2015, 32, 343-352.	1.2	61
10	Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 670-674.	1.2	58
11	Epicardial adipose tissue predicts incident cardiovascular disease and mortality in patients with type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2019, 18, 114.	2.7	57
12	Higher Collagen VI Formation Is Associated With All-Cause Mortality in Patients With Type 2 Diabetes and Microalbuminuria. <i>Diabetes Care</i> , 2018, 41, 1493-1500.	4.3	51
13	Markers of inflammation and endothelial dysfunction are associated with incident cardiovascular disease, all-cause mortality, and progression of coronary calcification in type 2 diabetic patients with microalbuminuria. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 248-255.	1.2	49
14	Epicardial and pericardial adipose tissues are associated with reduced diastolic and systolic function in type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2006-2011.	2.2	44
15	Targeting epicardial adipose tissue with exercise, diet, bariatric surgery or pharmaceutical interventions: A systematic review and meta-analysis. <i>Obesity Reviews</i> , 2021, 22, e13136.	3.1	43
16	Abnormal echocardiography in patients with type 2 diabetes and relation to symptoms and clinical characteristics. <i>Diabetes and Vascular Disease Research</i> , 2016, 13, 321-330.	0.9	42
17	Symmetric and asymmetric dimethylarginine as risk markers of cardiovascular disease, all-cause mortality and deterioration in kidney function in persons with type 2 diabetes and microalbuminuria. <i>Cardiovascular Diabetology</i> , 2017, 16, 88.	2.7	41
18	Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: a sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 901-905.	2.2	39

#	ARTICLE	IF	CITATIONS
19	Epicardial adipose tissue: an emerging biomarker of cardiovascular complications in type 2 diabetes?. Therapeutic Advances in Endocrinology and Metabolism, 2020, 11, 204201882092882.	1.4	38
20	Urinary proteomics for prediction of mortality in patients with type 2 diabetes and microalbuminuria. Cardiovascular Diabetology, 2018, 17, 50.	2.7	36
21	Additive prognostic value of plasma N-terminal pro-brain natriuretic peptide and coronary artery calcification for cardiovascular events and mortality in asymptomatic patients with type 2 diabetes. Cardiovascular Diabetology, 2015, 14, 59.	2.7	35
22	No Evidence of Increase in Calcitonin Concentrations or Development of C-Cell Malignancy in Response to Liraglutide for Up to 5 Years in the LEADER Trial. Diabetes Care, 2018, 41, 620-622.	4.3	35
23	Effect of large weight reductions on measured and estimated kidney function. BMC Nephrology, 2017, 18, 52.	0.8	34
24	Effect of Liraglutide on Cardiovascular Outcomes in Elderly Patients: A Post Hoc Analysis of a Randomized Controlled Trial. Annals of Internal Medicine, 2019, 170, 423.	2.0	34
25	Epicardial, pericardial and total cardiac fat and cardiovascular disease in type 2 diabetic patients with elevated urinary albumin excretion rate. European Journal of Preventive Cardiology, 2017, 24, 1517-1524.	0.8	33
26	Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 465-473.	2.2	32
27	Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial. Diabetes Care, 2021, 44, 1020-1026.	4.3	30
28	Growth differentiation factor-15 and fibroblast growth factor-23 are associated with mortality in type 2 diabetes – An observational follow-up study. PLoS ONE, 2018, 13, e0196634.	1.1	29
29	Urinary biomarkers are associated with incident cardiovascular disease, all-cause mortality and deterioration of kidney function in type 2 diabetic patients with microalbuminuria. Diabetologia, 2016, 59, 1549-1557.	2.9	25
30	Urinary tubular biomarkers as predictors of kidney function decline, cardiovascular events and mortality in microalbuminuric type 2 diabetic patients. Acta Diabetologica, 2018, 55, 1143-1150.	1.2	23
31	Cardiac Autonomic Function Is Associated With the Coronary Microcirculatory Function in Patients With Type 2 Diabetes. Diabetes, 2016, 65, 3129-3138.	0.3	22
32	Interleukin 6 in diabetes, chronic kidney disease, and cardiovascular disease: mechanisms and therapeutic perspectives. Expert Review of Clinical Immunology, 2022, 18, 377-389.	1.3	22
33	Effect of liraglutide on expression of inflammatory genes in type 2 diabetes. Scientific Reports, 2021, 11, 18522.	1.6	21
34	Plasma trimethylamine N-oxide and its metabolic precursors and risk of mortality, cardiovascular and renal disease in individuals with type 2-diabetes and albuminuria. PLoS ONE, 2021, 16, e0244402.	1.1	20
35	Toe-brachial index as a predictor of cardiovascular disease and all-cause mortality in people with type 2 diabetes and microalbuminuria. Diabetologia, 2017, 60, 1883-1891.	2.9	18
36	Effect of Liraglutide on Arterial Inflammation Assessed as [¹⁸ F]FDG Uptake in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial. Circulation: Cardiovascular Imaging, 2021, 14, e012174.	1.3	18

#	ARTICLE	IF	CITATIONS
37	Relation of cardiac adipose tissue to coronary calcification and myocardial microvascular function in type 1 and type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2020, 19, 16.	2.7	16
38	Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the <sc>ADJUNCT ONE</sc> and <sc>ADJUNCT TWO</sc> randomized controlled trials. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2752-2762.	2.2	16
39	Effect of 26 Weeks of Liraglutide Treatment on Coronary Artery Inflammation in Type 2 Diabetes Quantified by [64Cu]Cu-DOTATATE PET/CT: Results from the LIRAFLAME Trial. <i>Frontiers in Endocrinology</i> , 2021, 12, 790405.	1.5	16
40	Prevalence of Diabetic Neuropathy in Young Adults with Type 1 Diabetes and the Association with Insulin Pump Therapy. <i>Diabetes Technology and Therapeutics</i> , 2018, 20, 787-796.	2.4	15
41	Aetiological factors behind adipose tissue inflammation: an unexplored research area. <i>Public Health Nutrition</i> , 2013, 16, 27-35.	1.1	14
42	Ceramides and phospholipids are downregulated with liraglutide treatment: results from the LiraFlame randomized controlled trial. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e002395.	1.2	14
43	Pleiotropic effects of liraglutide treatment on renal risk factors in type 2 diabetes: Individual effects of treatment. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 162-168.	1.2	13
44	Cardiac Autonomic Function Is Associated With Myocardial Flow Reserve in Type 1 Diabetes. <i>Diabetes</i> , 2019, 68, 1277-1286.	0.3	13
45	Myocardial flow reserve assessed by cardiac 82Rb positron emission tomography/computed tomography is associated with albumin excretion in patients with Type 1 diabetes. <i>European Heart Journal Cardiovascular Imaging</i> , 2019, 20, 796-803.	0.5	13
46	The influence of pharmaceutically induced weight changes on estimates of renal function: A patient-level pooled analysis of seven randomised controlled trials of glucose lowering medication. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 1146-1151.	1.2	10
47	Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the <sc>LEADER</sc> randomized trial. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2077-2088.	2.2	10
48	Current state of antigen-specific immunotherapy for type 1 diabetes. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2021, Publish Ahead of Print, 411-418.	1.2	10
49	Pleiotropic effects of liraglutide in patients with type 2 diabetes and moderate renal impairment: Individual effects of treatment. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1261-1265.	2.2	9
50	Impaired coronary microcirculation in type 2 diabetic patients is associated with elevated circulating regulatory T cells and reduced number of IL-21R+ T cells. <i>Cardiovascular Diabetology</i> , 2016, 15, 67.	2.7	8
51	The effect of liraglutide and sitagliptin on oxidative stress in persons with type 2 diabetes. <i>Scientific Reports</i> , 2021, 11, 10624.	1.6	8
52	Liraglutide reduces cardiac adipose tissue in type 2 diabetes: A secondary analysis of the <sc>LIRAFLAME</sc> randomized <sc>placebo-controlled</sc> trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2651-2659.	2.2	7
53	High osteoprotegerin is associated with development of foot ulcer in type 1 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 1603-1608.	1.2	6
54	Effect of weight reductions on estimated kidney function: Post-hoc analysis of two randomized trials. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 1164-1168.	1.2	6

#	ARTICLE	IF	CITATIONS
55	Effect of Liraglutide on Vascular Inflammation Evaluated by [64Cu]DOTATATE. <i>Diagnostics</i> , 2021, 11, 1431.	1.3	5
56	The importance of addressing multiple risk markers in type 2 diabetes: Results from the <scp>LEADER</scp> and <scp>SUSTAIN</scp> 6 trials. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 281-288.	2.2	5
57	Urinary Alpha- and Pi-Glutathione S-Transferases in Adult Patients with Type 1 Diabetes. <i>Nephron Extra</i> , 2014, 4, 127-133.	1.1	4
58	Higher Parathyroid Hormone Level Is Associated With Increased Arterial Stiffness in Type 1 Diabetes. <i>Diabetes Care</i> , 2017, 40, e32-e33.	4.3	4
59	Lipoprotein(a)and renal function decline, cardiovascular disease and mortality in type 2 diabetes and microalbuminuria. <i>Journal of Diabetes and Its Complications</i> , 2020, 34, 107593.	1.2	4
60	Nonâ€invasive assessment of temporal changes in myocardial microvascular function in persons with type 2 diabetes and healthy controls. <i>Diabetic Medicine</i> , 2021, 38, e14517.	1.2	4
61	The Association Between Cardiovascular Autonomic Function and Changes in Kidney and Myocardial Function in Type 2 Diabetes and Healthy Controls. <i>Frontiers in Endocrinology</i> , 2021, 12, 780679.	1.5	4
62	Insulin at 100: still central in protein-based therapy for chronic disease. <i>Communications Medicine</i> , 2021, 1, .	1.9	2
63	Response by Mann et al to Letter Regarding Article, â€œEffects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: Results From the LEADER Trialâ€ Circulation, 2019, 139, e1017-e1018.	1.6	1
64	FC 058THE IMPORTANCE OF ADDRESSING MULTIPLE RISK MARKERS IN TYPE 2 DIABETES: RESULTS FROM THE LEADER AND SUSTAIN 6 TRIALS. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	1
65	The effect of liraglutide on cardiac autonomic function in type 2 diabetes: A prespecified secondary analysis from the <scp>LIRAFLAME</scp> randomized, doubleâ€blinded, placeboâ€controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1638-1642.	2.2	1
66	1.4 A PROTEOMIC MARKER OF DIABETIC NEPHROPATHY IS ASSOCIATED WITH MORTALITY IN PATIENTS WITH TYPE 2 DIABETES. <i>Artery Research</i> , 2017, 20, 48.	0.3	0
67	SP418COLLAGEN TYPE III DEGRADATION IS ASSOCIATED WITH DETERIORATION OF KIDNEY FUNCTION IN PATIENTS WITH TYPE 2 DIABETES WITH MICROALBUMINURIA.. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i488-i488.	0.4	0
68	675-P: Effects of Liraglutide in T1D by Baseline Anthropometrics in ADJUNCT One and Two. <i>Diabetes</i> , 2021, 70, .	0.3	0
69	1532-P: Investigating Biomarkers of the Immune Response and Tissue Remodeling in Patients with Type 2 Diabetes with Microalbuminuria. <i>Diabetes</i> , 2020, 69, 1532-P.	0.3	0
70	Editorial: Advanced Cardiovascular Imaging in Diabetes. <i>Frontiers in Endocrinology</i> , 2022, 13, 848975.	1.5	0